Eligible patients: Patients with estrogen receptor positive (ER+), metastatic ILC. Patients who are treatment naive or have received up to 2 lines of therapy in the metastatic setting.
Description of Trial/Summary: This phase 2 clinical trial compares two types of cancer imaging scans to see which is better at detecting and monitoring disease in patients with metastatic invasive lobular carcinoma (ILC). The study will compare 18F- fluoroestradiol (FES) PET/CT with 18F-fluorodeoxyglucose (FDG) detecting and monitoring metastatic ILC.
Background: Detecting ILC is challenging on any imaging modality. FDG PET/CT is currently used to detect and monitor treatment in patients with ILC, however, ILC is known to have low uptake on FDG, limiting detection and its utility for ILC patients. FES is a newer PET tracer designed to detect estrogen receptors, which almost all lobular breast cancers express. Through improved detection, FES PET/CT may improve cancer detection and treatment decisions compared to our standard imaging methods.
Why is this study beneficial/Important?: FES PET/CT is an FDA-approved imaging test for detecting metastatic or recurrent ER+ breast cancers. Almost all ILC (~95%) is ER+ and thus, we believe FES PET targeting estrogen receptors may be better than FDG PET/CT, one of the standard imaging tests for metastatic ILC, and allow for better cancer detection and treatment decisions.
Principal Investigator: Randy Yeh, MD, Memorial Sloan Kettering Cancer Center
How to learn more about whether participating in this trial is right for you:
Contact David Roy, Clinical Research Associate at royd2@mskcc.org or
Randy Yeh at yehr@mskcc.org
Trial location: Memorial Sloan Kettering Cancer Center (Main Hospital and Regional sites)
More Information: https://clinicaltrials.gov/study/NCT06557148
To learn more about FES PET Imaging: https://lobularbreastcancer.org/lbca-scientific-blog/
